Evaluating anticancer effects of geraniin supplementation in a syngeneic mouse model of breast cancer: Identification of differentially regulated plasma proteins
Year: 2025
Type: article
Abstract: Geraniin, an ellagitannin present in many seeds, nuts, fruits, and plants, has anticancer, antioxidant, antiviral, antimicrobial, antimutagenic, cardiovascular protective, and hypoglycemic properties. Geraniin was tested for its anticancer and plasma protein-modifying properties in a syngeneic mouse model of breast cancer (BC). A mouse mammary cancer cell line (4T1) was injected into the mammary pad of female BALB/c mice to produce BC. Daily oral gavage of geraniin (0.5 mg) or soy oil was given to animals having visible tumors. For 6 – 7 weeks, tumor growth was evaluated. At postmortem, cancer tissue was removed for histopathology, and the plasma was analyzed using a commercial protein array platform. Geraniin supplementation reduced tumor growth and liver metastasis (p<0.05) and altered 20 plasma proteins, including Tropomyosin 3 (TPM3), catenin beta-1 (CTNNB1), hemopoietic lineage cell-specific protein 1 (HCLS1), and Serine/threonine-protein kinase 10 (STK10). Six biomarkers (RAD23 homolog B, HCLS1, CTNNB1, A type of type ll restriction enzyme, TPM3, and STK10) were higher in geraniin-treated samples than in control samples, regardless of tumor induction. Monitoring plasma protein expression in a BC model indicated tumor progression, metastasis, and potential diagnostic or therapeutic biomarkers. The 4T1 cell line, an exceptionally invasive mammary cancer model, accurately replicates human triple-negative BC, making it valuable for investigating metastatic behavior and treatment. Plasma protein dynamics in this model may identify tumor aggressiveness regulators and therapeutic targets. Geraniin possesses antitumor and anti-metastasis characteristics and could be developed to treat BC. The autoantibody response toward these antigens and fluctuation in the response could suggest a potential marker or a predictive marker toward treatment with geraniin.
Source: Cancer Plus
DOI: 10.36922/cp.7115
Authors: Heng Jia Hui, Catherine Ng Zhi Xin, Nur Diana Anuar, Jeya Seela Anandha Rao, Nurul H Rutt, Nurul Shielawati Mohamed Rosli, Sunil Pazhayanur Venkateswaran, Ammu Kutty Radhakrishnan
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4409454979